Recommended Topic Related To:

Buminate

"Nov. 28, 2012 -- Many pork chops and ground pork products in the U.S. may be tainted with antibiotic-resistant bacteria, including one that the USDA does not look for, a Consumer Reports study shows.

The new report also found"...

Buminate 25%

BUMINATE 25%
Albumin (Human), USP, 25% Solution

This bottle contains 25 g albumin from venous plasma in buffered diluent and is osmotically equivalent to 500 mL of normal human plasma. It has been stabilized with sodium caprylate and sodium acetyltryptophanate and heated for 10 hours at 60°C. The sodium content is 145 ± 15 mEq/L. Contains no preservative. Store at room temperature, not to exceed 30°C (86°F). Avoid freezing to prevent damage to the bottle. See attached directions for use. Caution: In patients with marked dehydration additional fluids must accompany or follow administration of this product. Do not use if turbid. Do not begin administration more than 4 hours after the container has been entered. Single dose container. Discard partially used bottle.

The patient and physician should discuss the risks and benefits of this product.

DRUG DESCRIPTION

BUMINATE 25%, Albumin (Human), 25% Solution is a sterile, nonpyrogenic preparation of albumin in a single dosage form for intravenous administration. Each 100 mL contains 25 g of albumin and is prepared from human venous plasma using the Cohn cold ethanol fractionation process. Source material for fractionation may be obtained from another U.S. licensed manufacturer. It has been adjusted to physiological pH with sodium bicarbonate and/or sodium hydroxide and stabilized with sodium acetyltryptophanate and sodium caprylate. The sodium content is 145 ± 15 mEq/L. This solution contains no preservative and none of the coagulation factors found in fresh whole blood or plasma. BUMINATE 25%, Albumin (Human), 25% Solution is a transparent or slightly opalescent solution which may have a greenish tint or may vary from a pale straw to an amber color.

The likelihood of the presence of viable hepatitis viruses has been minimized by heating the product for 10 hours at 60°C. This procedure has been shown to be an effective method of inactivating hepatitis virus in albumin solutions even when those solutions were prepared from plasma known to be infective.1-3

REFERENCES

1. Gellis SS, Neefe JR, Stokes J Jr, et al: Chemical, clinical and immunological studies on the products of human plasma fractionation. XXXVI. Inactivation of the virus of homologous serum hepatitis in solutions of normal human serum albumin by means of heat. J Clin Invest 27:239-244, 1948

2. Gerety RJ, Aronson DL: Plasma derivatives and viral hepatitis. Transfusion 22:347-351, 1982

3. Murray R, Diefenbach WCL, Geller H, et al: Problem of reducing danger of serum hepatitis from blood and blood products. NY State J Med 55:1145-1150, 1955

Last reviewed on RxList: 1/20/2009
This monograph has been modified to include the generic and brand name in many instances.

A A A

Report Problems to the Food and Drug Administration

 

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.


Weight Loss Wisdom

Get tips, recipes and inspiration.


From WebMD